BRCA1: Mechanisms of inactivation and implications for management of patients

Lancet

Volumn 360, Issue 9338, 2002, Pages 1007-1014

  Kennedy, Richard D ^a   Quinn, Jennifer E ^a   Johnston, Patrick G ^a   Harkin, D Paul ^a  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN;

BREAST CARCINOMA; CANCER PREVENTION; CANCER SURGERY; DNA REPAIR; GENE CONTROL; GENE INACTIVATION; GENE MUTATION; GENETIC ANALYSIS; GENETIC PREDISPOSITION; GENETIC PROCEDURES; GENETIC TRANSCRIPTION; HIGH RISK POPULATION; MALIGNANT TRANSFORMATION; MOLECULAR CLONING; OVARY CARCINOMA; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SIGNAL TRANSDUCTION;

EID: 0037190607     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(02)11087-7     Document Type: Review

References (81)

1. Hall J.M., Lee M.K., Newman B., et al. Linkage of early-onset breast familial breast cancer to chromosome 17q21. Science. 250:1990;1684-1689.
2. Miki Y., Swensen J., Shattuck-Eidens D., et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science. 266:1994;66-71.
3. Monteiro A.N., August A., Hanafusa H. Evidence for a transcriptional activation function of BRCA1 C-terminal region. Proc Natl Acad Sci USA. 93:1996;13595-13599.
4. Koonin E.V., Altschul S.F., Bork P. BRCA1 protein products...functional motifs... Nat Genet. 13:1996;266-268.
5. Bork P., Hofmann K., Bucher P., Neuwald A.F., Altschul S.F., Koonin E.V. A superfamily of conserved domains in DNA damage-responsive cell cycle checkpoint proteins. FASEB J. 11:1997;68-76.
6. Kerr P., Ashworth A. New complexities for BRCA1 and BRCA2. Curr Biol. 11:2001;668-676.
7. Ford D., Easton D.F., Bishop D.T., Narod S.A., Godgar D.E. Risks of cancer in BRCA1-mutation carriers. Lancet. 343:1994;692-695.
8. Marquis S.T., Rajan J.V., Wynshaw-Boris A., et al. The developmental pattern of Brca1 expression implies a role in differentiation of the breast and other tissues. Nat Genet. 11:1995;17-26.
9. Futreal P.A., Liu Q., Shattuck-Eidens D., et al. BRCA1 mutations in primary breast and ovarian carcinomas. Science. 266:1994;120-122.
10. Friedman L.S., Ostermeyer E.A., Szabo C.I., et al. Confirmation of BRCA1 by analysis of germline mutations linked to breast and ovarian cancer in ten families. Nat Genet. 8:1994;399-404.
11. Bahar A.Y., Taylor P.J., Andrews L., et al. The frequency of founder mutations in the BRCA1, BRCA2 and APC genes in Australian Ashkenazi Jews: implications for the generality of US population data. Cancer. 92:2001;440-445.
12. Narod S.A. Modifiers of risk of hereditary breast and ovarian cancer. Nat Rev Cancer. 2:2002;113-123.
13. Thompson M.E., Jensen R.A., Obermiller P.S., Page O.L., Holt J.T. Decreased expression of BRCA1 accelerates growth and is often present during sporadic breast cancer progression. Nat Genet. 9:1995;444-450.
14. Yang Q., Sakurai T., Mori I., et al. Prognostic significance of BRCA1 expression in Japanese sporadic breast carcinomas. Cancer. 92:2001;54-60.
15. Sourvinos G., Spandidos D.A. Decreased BRCA1 expression levels may arrest the cell cycle through activation of p53 checkpoint in human sporadic breast tumours. Biochem Biophys Res Commun. 245:1998;75-80.
16. Xu C.F., Chambers J.A., Nicolai H., et al. Mutations and alternative splicing of the BRCA1 gene in UK breast/ovarian families. Genes Chromosomes Cancer. 18:1997;102-110.
17. Rice J.C., Massey-Brown K.S., Futscher B.W. Aberrant methylation of the BRCA1 CpG island promoter is associated with decreased mRNA in sporadic breast cancer cells. Oncogene. 17:1998;1807-1812.
18. Scully R., Chen J., Ochs R.L., et al. Dynamic changes of BRCA1 subnuclear location and phosphorylation state are initiated by DNA damage. Cell. 90:1997;425-435.
19. Ford D., Easton D.F., Peto J. Estimates of the gene frequency of BRCA1 and its contribution to breast and ovarian incidence. Am J Hum Genet. 57:1995;1457.
20. Couch F.J., Hartmann L.C. BRCA1 testing: advances and retreats. JAMA. 279:1998;955-957.
21. American Society of Clinical Oncology . Statement of the American Society of Clinical Oncology: genetic testing for cancer suscepitibilty. J Clin Oncol. 14:1996;1730-1736.
22. Cancer Research UK Primary Care Education Research Group. Familial Breast and Ovarian Cancer: A Management Guide for Primary Care - March, 2001. http://www.dphpc.ox.ac.uk/crcpcerg/resources/CRCBrochure.pdf (accessed July 11, 2002).
23. Shannon K.M., Lubratovich M.L., Finkelstein D.M. Model-based predictions of BRCA1/2 mutation status in breast carcinoma patients treated at an academic medical center. Cancer. 94:2002;305-313.
24. Lakhani S.R., van de Vijver M., Jacquemier J., et al. The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, Her-2 and p53 in patients with mutations in BRCA1 and BRCA2. J Clin Oncol. 20:2002;2310-2318.
25. Peshkin B., Lerman C. Genetic counselling for hereditary breast cancer. Lancet. 353:1999;2176-2177.
26. Cappelli M., Surh L., Humphreys L., et al. Psychological and social determinants of women's decisions to undergo genetic counselling and testing for breast cancer. Clin Genet. 55:1999;419-4130.
27. Haffty B.G., Harrold E., Khan A.J., et al. Outcome of conservatively managed early-onset breast cancer by BRCA1/2 status. Lancet. 359:2002;1471-1477.
28. Hartmann L.C., Sellers T.A., Schaid T.A., et al. Efficacy of bilateral prophylactic mastectomy in BRCA1 and BRCA2 gene mutation carriers. J Natl Cancer Inst. 93:2001;1633-1637.
29. Meijers-Heijboer H., van Geel B., van Putten W.L. Breast cancer after prophylactic mastectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med. 345:2001;159-164.
30. NIH Consensus Development Panel On Ovarian Cancer. Ovarian Cancer: Screening, Treatment, and Follow-up. JAMA 1995; 273: 491-97.
31. Kauff N.D., Satagopan J.M., Robson M.E., et al. Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med. 346:2002;1609-1615.
32. Rebbeck T.R., Lynch H.T., Neuhausen S.L., et al. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med. 346:2002;1616-1622.
33. Colgan T.J., Murphy J., Cole D.E., Narod S., Rosen B. Occult carcinoma in prophylactic oophorectomy specimens: prevalence and association with BRCA germline mutation status. Am J Surg Pathol. 25:2001;1283-1289.
34. Paley P.J., Swisher E.M., Garcia R.L., et al. Occult cancer of the fallopian tube in BRCA-1 germline mutation carriers at prophylactic oophorectomy: a case for recommending hysterectomy at surgical prophylaxis. Gynaecol Oncol. 80:2001;176-180.
35. Piver M.S., Jishi M.F., Tsukada Y., Nava G. Primary peritoneal carcinoma after prophylactic oophorectomy in women with a family history of ovarian cancer: a report of the Gilda Radner Familial Ovarian Cancer Registry. Cancer. 71:1993;2751-2755.
36. Hatcher M.B., Fallowfield L., A'Hern R. The psychosocial impact of bilateral prophylactic mastectomy: prospective study using questionnaires and semistructured interviews. BMJ. 322:2001;76.
37. Eisen A, Rebbeck TR, Wood WC, Weber BL. Prophylactic surgery in women with a hereditary predisposition to breast and ovarian cancer. J Clin Oncol 2000; 18: 1980-95.
38. Rawat N. Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer (Cochrane Review). The Cochrane Library. 2001;Update Software, Oxford.
39. Phillips K.A., Andrulis I.L., Goodwin P.J. Breast carcinomas arising in carriers of mutations in BRCA1 or BRCA2: are they prognostically different? J Clin Oncol. 17:1999;3653-3663.
40. Jernstrom H.C., Lerman P., Ghadirian P., et al. Pregnancy and risk of early onset breast cancer in carriers of BRCA1 and BRCA2. Lancet. 354:1999;1846-1850.
41. Narod S.A., Brunet J.S., Ghadirian P., et al. Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study. Lancet. 356:2000;1876-1881.
42. Fisher B., Costantino J.P., Wickerham D.L., et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst. 90:1998;1371-1388.
43. King M.C., Wieand S., Hale K., et al. Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2: National Surgical Adjuvant Breast and Bowel Project (NSABP-P1) Breast Cancer Prevention Trial. JAMA. 286:2001;2251-2256.
44. Powles T.J. The Royal Marsden Hospital (RMH) trial: key points and remaining questions. Ann N Y Acad Sci. 949:2001;109-112.
45. Barton D.L., Loprinzi C., Gostout B. Current management of menopausal symptoms in cancer patients. Oncology. 16:2002;67-72.
46. Narod S.A., Risch H., Moslehi R., et al. Oral contraceptives and the risk of hereditary ovarian cancer. N Engl J Med. 339:1998;424-428.
47. Modan B., Hartge P., Hirsh-Yechezkel G., et al. Parity, oral contraceptives, and the risk of ovarian cancer among carriers and noncarriers of a BRCA1 or BRCA2 Mutation. N Engl J Med. 345:2001;235-240.
48. Ursin G., Henderson B.E., Haile R.W., et al. Does oral contraceptive use increase the risk of breast cancer in women with BRCA1/BRCA2 mutations more than in other women? Cancer Res. 57:1997;3678-3681.
49. Armstrong K., Weber B. Breast cancer screening for high-risk women: too little, too late? J Clin Oncol. 19:2001;919-920.
50. Brekelmans C.T., Seynaeve C., Bartels C.C., et al. Effectiveness of breast cancer surveillance in BRCA1/2 gene mutation and women with high familial risk. J Clin Oncol. 19:2001;924-930.
51. Muto M.G., Cramer D.W., Brown D.L., et al. Screening for ovarian cancer: the prelimary experience of a familial ovarian cancer center. Gynecol Oncol. 51:1993;12-20.
52. van Nagell J.R. Jr, DePriest P.D., Reedy M.B., et al. The efficacy of transvaginal sonographic screening in asymptomatic women at risk for ovarian cancer. Gynaecol Oncol. 77:2000;350-356.
53. Einhorn N., Bast R., Knapp R., Nillson B., Zurawski V., Sjovall K. Long-term follow-up of the Stockholm screening study on ovarian cancer. Gynecol Oncol. 79:2000;466-467.
54. van Roosmalen M.S., Verhoef L.C.G., Stalmeier P.F.M. Decision analysis of prophylactic surgery or screening for BRCA1 mutation carriers: a more prominent role for oophorectomy. J Clin Oncol. 20:2002;2092-2100.
55. Chapman M.S., Verma I.M. Transcriptional activation by BRCA1. Nature. 382:1996;678-679.
56. Brodie S.G., Xu X., Qiao W., Li W.M., Cao L., Deng C.X. Multiple genetic changes are associated with mammary tumorigenesis in BRCA1 conditional knockout mice. Oncogene. 20:2001;7514-7523.
57. Breast Cancer Linkage Consortium. Pathology of familial breast cancer: Differences between breast cancers in carriers of BRCA1 and BRCA2 mutations and sporadic cases. Lancet 1997; 349: 1505-10.
58. Hedenfalk I, Duggan D, Chen Y, et al. Gene-expression profiles in hereditary breast cancer. N Engl J Med; 344: 539-48.
59. Robson M., Gilewski T., Haas B., et al. BRCA-associated breast cancer in young women. J Clin Oncol. 16:1998;1642-1649.
60. Verhoog L.C., Brekelmans C.T., Seynaeve C., et al. Survival and tumour characteristics of breast-cancer patients with germline mutations of BRCA1. Lancet. 351:1998;316-321.
61. Hamann U., Sinn H.P. Survival and tumor characteristics of German herediary breast cancer patients. Breast Cancer Res Treat. 59:2000;185-192.
62. Chappuis P.O., Kapusta L., Begin L.R., et al. Germline BRCA1/2 mutations and p27(Kip1) protein levels independently predict outcome after breast cancer. J Clin Oncol. 18:2000;4045-4052.
63. Rubin S.C., Benjamin I., Behbakht K., et al. Clinical and pathological features of ovarian cancer in women with germ-line mutations of BRCA1. N Engl J Med. 335:1996;1413-1416.
64. Brunet J.S., Narod S.A., Tonin P., Foulkes W.D. BRCA1 mutations and survival in women with ovarian cancer. N Engl J Med. 336:1997;1256.
65. Ben David Y., Chetrit A., Hirsh-Yechezkel G., et al. Effect of BRCA mutations on the length of survival in epithelial ovarian tumours. J Clin Oncol. 20:2002;463-466.
66. Johannsson O.T., Ranstan J., Borg A., Olsson H. Survival of BRCA1 breast and ovarian cancer patients: a population-based study from southern Sweden. J Clin Oncol. 16:1998;397-404.
67. van't Veer L.J., Dai H., van de Vijver M.J., et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature. 415:2002;530-536.
68. Geisler J.P., Hatterman-Zogg M.A., Rathe J.A., Buller R.E. Frequency of BRCA1 dysfunction in ovarian cancer. J Natl Cancer Inst. 94:2002;61-67.
69. Pierce L.J., Strawderman M., Narod S.A., et al. Effect of radiotherapy after breast-conserving treatment in women with breast cancer and germline BRCA1/2 mutations. J Clin Oncol. 18:2000;3360-3369.
70. Kloos I, Delaloge S, Chompret A, et al. BRCA1/2-linked breast carcinoma is a highly chemosensitive disease. Proc Annu Meet Am Soc Clin Oncol, 2001 (abstr 1862).
71. Moynahan M.E., Chiu J.W., Koller B., Jasin M. BRCA1 controls homology-directed DNA repair@ Mol Cell. 4:1999;511-518.
72. Henderson IC, Berry D, Demetri G, et al. Improved disease-free and overall survival from the addition of sequential paclitaxel but not from the escalation of doxorubicin dose level in the adjuvant chemotherapy of patients with node-positive breast cancer. Proc Annu Meet Am Soc Clin Oncol, 1998 (abstr 390).
73. Mamoumas E. Paclitaxel following doxorubicin/cyclophosphamide in node-positive breast cancer: Third term analysis of NSABP B.28. Bethesda: Program and Abstracts of National Institutes of Health Consensus Development Conference on Adjuvant Therapy for Breast Cancer, 2000.
74. Mullan P.B., Quinn J.E., Gilmore P.M., et al. BRCA1 and GADD45 mediated G2/M cell cycle arrest in response to antimicrotubule agents. Oncogene. 20:2001;6123-6131.
75. Lafarge S., Sylvain V., Ferrara M., Bignon Y.J. Inhibition of BRCA1 leads to increased chemoresistence to microtubule-interfering agents, an effect that involves the JNK pathway. Oncogene. 20:2001;6597-6606.
76. Maresco DL, Arnold P, Bogomolny F, et al. Role of BRCA1 in response to therapeutic DNA-damaging agents in human breast cancer cells. Proc Annu Meet Am Soc Clin Oncol, 2001 (abstr 175).
77. Hsu L.C., White R.L. BRCA1 is associated with the centrosome during mitosis. Proc Natl Acad Sci. 95:1998;12983-12988.
78. Xu X., Weaver Z., Linke S.P., et al. Centrosome amplification and a defective G2M cell cycle checkpoint induce genetic instablility in BRCA1 exon 11 isoform-deficient cells. Mol Cell. 3:1999;389-395.
79. Egawa C., Miyoshi Y., Takamura Y., Taguchi T., Tamaki Y. Decreased expression of BRCA2 mRNA predicts favorable response to docetaxel in breast cancer. Int J Cancer. 95:2001;255-259.
80. Harkin D.P., Bean J.M., Miklos D., et al. Induction of GADD45 and JNK/SAPK-dependent apoptosis following inducible expression of BRCA1. Cell. 97:1999;575-586.
81. Mullan P.B., McWilliams S., Quinn J.E., et al. Uncovering BRCA1 regulated signalling pathways by microarray-based expression profiling. Biochem Soc Trans. 29:2001;678-683.